Survodutide Dosage: 4.8mg/Week Titration Protocol

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Phase 2 participants receiving 4.8 mg weekly lost up to 18.7% of body weight over 46 weeks — with the glucagon component adding thermogenic and hepatic fat-oxidation effects that Phase 2 trial analyses attributed to the dual-agonist mechanism.

Research-context information only. Survodutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

Survodutide is not FDA-approved. It is currently in Phase 3 clinical trials. Everything below reflects published clinical trial data. This is not medical advice.

Quick Reference: Clinical Trial Protocol

Titration Schedule

The Phase 2 trial used gradual dose escalation to minimize GI side effects. Each level was maintained ~4 weeks before increasing:

Participants who couldn't tolerate an increase could remain at their current level or reduce. Not all reached 4.8 mg — the "actual doses received" analysis showed 18.7% weight loss vs. 14.9% in the intention-to-treat group.

Cycling Details

Survodutide does not use traditional peptide cycling. Clinical trials ran continuously for 46 weeks with the titration schedule above. No on/off cycling data exists — this is a drug in active clinical development, not a research peptide with community-derived cycling protocols.

Routes of Administration

Subcutaneous injection is the only route. Survodutide cannot be taken orally.

• Sites: Abdomen, thigh, or upper arm — rotate weekly
• Timing: Same day each week, any time of day
• Missed dose: Phase 2 trial protocols described the following missed-dose guidance: if the missed injection fell within 3 days of the scheduled date, it was taken on that date; if more than 3 days late, it was skipped and the regular weekly schedule resumed.

Reconstitution Quick Reference

If using research-grade lyophilized survodutide:

Math: 10 mg / 2 mL = 5 mg/mL. For 4.8 mg: 4.8 / 5 = 0.96 mL = 96 units.

Community reconstitution protocols describe gentle swirling rather than shaking; refrigeration and use within 28 days is the documented standard. For the full reconstitution walkthrough, see our Survodutide Reconstitution Guide.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Phase 2 obesity trial: Four dose groups tested against placebo (Bluher et al., 2024):

The gap between "planned" and "actual" at 4.8 mg is significant — participants who tolerated the full dose achieved substantially greater weight loss.

Phase 2 diabetes trial: Dose-dependent improvements in HbA1c and weight in patients with T2D (Bluher et al., 2024).

Dual-agonist mechanism: GLP-1 suppresses appetite and slows gastric emptying. Glucagon increases energy expenditure and hepatic fat oxidation. The combination uniquely targets liver fat — survodutide has strong MASH (metabolic-associated steatohepatitis) data.

Stacking Protocols

Survodutide stacking data does not exist from clinical trials. As an investigational dual agonist, combining with other GLP-1-targeting compounds (semaglutide, tirzepatide, retatrutide) would be redundant and increase side effects.

Side Effects & Safety

• Nausea — most common, worst during dose escalation
• Vomiting — more common at higher doses
• Diarrhea — dose-dependent
• Decreased appetite — expected pharmacological effect
• Heart rate increases — small, consistent with GLP-1 class
• Liver enzymes (ALT/AST) — trial protocols tracked these due to glucagon receptor effects on liver metabolism
• Lipase/amylase — standard monitored endpoint across GLP-1 class trials
• Thyroid C-cell warning — GLP-1 class concern from rodent studies
• GI adverse events occurred in 75% of survodutide recipients vs 42% of placebo; most were mild-moderate

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once survodutide is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.